Stabilizers of transthyretin in amyloid cardiomyopathy: a systematic review and meta-analysis.

11 May 2024 (11:40 - 13:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Ms Lucrecia Maria Burgos

Instituto Cardiovascular De Buenos Aires, Buenos Aires (Argentina)

5 More presentations in this session

Presentation thumbnail

SGLT2 inhibitors in wild-type transthyretin amyloid cardiomyopathy: what to expect?

Doctor L. Pinheiro (Guimaraes, PT)

Abstract Slides Video

Presentation thumbnail

Therapeutic value of spironolactone in wild-type transthyretin amyloid cardiomyopathy

Doctor L. Pinheiro (Guimaraes, PT)

Abstract Slides Video

Presentation thumbnail

Improving survival rates of patients with light-chain cardiac amyloidosis in recent years

Doctor T. Nabeta (Sagamihara, JP)

Abstract Slides Video

Presentation thumbnail

Incidence and progression of left ventricular involvement in patients with arrythmogenic cardiomyopathy

Doctor A. Diaz Exposito (Malaga, ES)

Abstract Slides Video

Presentation thumbnail

Left ventricular non compaction in sub-saharan african adults

Doctor N. GAYE (Dakar, SN)

Abstract Slides Video

Access the full session

Session thumbnail

ePosters in myocardial disease 1

The Event

Event poster

Heart Failure 2024

11 May 2024 11:40 CET

You may be interested in

Congress Presentation

Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Congress Presentation

Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM

Congress Presentation

Effect of acoramidis on functional capacity and quality of life in patients with variant ATTR-CM: results from ATTRibute-CM

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources